Pharmaceutical industry is invited to respond to amnesty for unreported trials

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7109.683b (Published 13 September 1997) Cite this as: BMJ 1997;315:683
  1. Ian Roberts, Director (Ian.Roberts{at}ich.ucl.ac.uk)a
  1. aChild Health Monitoring Unit, Institute of Child Health, London WC1N 1EH

    See p 622

    Editor—Alan Maynard and Karen Bloor are correct to call for regulation of the pharmaceutical industry to ensure that all data from clinical trials are made publicly available.1 It is now well established that underreporting of clinical trials is a potent source of bias in the medical literature on the effectiveness of treatment and that research by the pharmaceutical industry is associated with a low publication rate (27%).2 3 The amnesty for unpublished trials announced today in the editorial by Smith and Roberts provides an opportunity for both non-industry and industry researchers, and the Association of the British Pharmaceutical Industry has been invited to respond positively to the initiative.


    1. 1.
    2. 2.
    3. 3.
    View Abstract

    Log in

    Log in through your institution


    * For online subscription